Abstract

BackgroundArsenic exposure increases the risk of non-cancerous and cancerous diseases. In the Antofagasta region in Chile, an established relationship exists between arsenic exposure and the risk of cancer of the bladder, lung and skin. Platinum-based drugs are first-line treatments, and many works recognise selenium as a cancer-fighting nutrient. We characterised the short-term urinary excretion amounts of arsenic, selenium and platinum in 24-h urine samples from patients with lung cancer and those with cancer other than lung treated with cisplatin or/and carboplatin. As - Se - Pt inter-element relationships were also investigated.ResultsThe amounts of platinum excreted in urine were not significantly different between patients with lung cancer and those with other cancers treated with cisplatin, despite the significant variation in platinum amounts supplied from platinum-based drugs. In general, the analytical amounts of excreted selenium were greater than those for arsenic, which could imply that platinum favours the excretion of selenium. For other types of cancers treated with drugs without platinum, excretion of selenium was also greater than that of arsenic, suggesting an antagonist selenium-anti-cancer drug relationship.ConclusionsRegards the baseline status of patients, the analytical amounts of excreted Se is greater than those for As, particularly, for cisplatin chemotherapy. This finding could imply that for over the As displacement Pt favours the excretion of Se. The analytical amounts of excreted Se were greater than those for As, either with and without Pt-containing drugs, suggesting an antagonist Se-anti-cancer drug relationship. However, it seemed that differences existed between As - Se - Pt inter-element associations in patients treated for lung cancer in comparison with those treated for cancer other than lung. Therefore, knowledge obtained in this work, can contribute to understanding the arsenic cancer mechanism and the As - Se - Pt inter-element association for lung cancer and other types of cancer, which in some cases respond at a linear mathematical model.

Highlights

  • Arsenic exposure increases the risk of non-cancerous and cancerous diseases

  • With the purpose of obtaining knowledge on the behavior and the inter-relationships among the endogen arsenic-selenium pair and platinum supplied as cisplatin and/or carboplatin, we investigated the excretion of As, Se and Pt in 24-h urine samples after the infusion of Pt based-drugs in five cancer patient groups coming from the Region II (Antofagasta) - Chile

  • Regarding the calculated drug-supplied platinum and the Pt, Se and As in urine, the results presented in Table 3 indicate that the decreasing tendency of supplied Pt was: carboplatin > cisplatin > cisplatin; the tendency of Pt amount in urine was the same as that of supplied Pt

Read more

Summary

Introduction

Arsenic exposure increases the risk of non-cancerous and cancerous diseases. In the Antofagasta region in Chile, an established relationship exists between arsenic exposure and the risk of cancer of the bladder, lung and skin. There has been deterioration in the environmental health of people living in the Region II (Antofagasta) in Chile This condition seems to be associated with medical geology characteristics of this part of the Atacama Desert ecosystem, geological structures in certain places on Earth influence human health [1,2] and the Cancerous and non-cancerous diseases associated with As contamination are known in several parts of the world [10]. This association reaches alarming levels in the Antofagasta region, as evidenced by the incidence of cardiovascular diseases [5] and cancer [4,7,11]. The metastasis [22] represents the principal disadvantage of these treatments

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call